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years. If 25 latanoprost patients were treated instead 
with travoprost, one new VFD would be avoided over 
5 years. CONCLUSION: According to our model, the
better control of both mean IOP and IOP variance by
travoprost should better preserve patient vision. Prospec-
tive data collection should be performed to conﬁrm our
ﬁndings.
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OBJECTIVE: To estimate the medical outcome of 
glaucoma/ocular hypertension (OH) treatment in France
according to usual practice. METHODS: Ophthalmolo-
gists selected at random had to include 4 consecutive
patients older than 18 seen in consultation during a week,
2 with glaucoma and 2 with OH. Socio-demographics,
general and eye comorbidities, glaucoma risk factors,
visual acuity (VA), papilla, and visual ﬁelds were col-
lected. A visual ﬁeld defect (VFD) was deﬁned as a dete-
rioration of papilla exam and visual ﬁeld since diagnosis.
A treatment switch was deﬁned as adding a new drug 
or changing any of the current treatments. Time to failure
of a treatment regimen, broken out by the number of
treatment switches, was compared using the likelihood
ratio applied to survival curves. RESULTS: One hundred
and twenty seven of the 337 patients included by the 84
ophthalmologists had their full treatment documented
from diagnosis. Twelve patients developed a new VFD
after diagnosis (average follow-up: 2.5 years). No statis-
tically signiﬁcant difference on the known confounding
factors of VFD was found between patients with and
without VFD. Patients with VFD had a lower VA (-1.23;
P < 0.08). At 3 years, 2.7% of the patients with no treat-
ment switch had a VFD, compared to 22.6% with one
treatment switch and 46.3% with >2 treatment switches.
The difference between the three groups was statistically
signiﬁcant (P < 0.01). CONCLUSION: Patients with
fewer treatment switches have less VFD. Under isotropic
hypotheses, effective treatment strategies should be used
ﬁrst line in order to avoid visual ﬁeld defect and there-
fore protect long-term patient vision.
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Skin diseases have a strong impact on physical and mental
well-being of the patient. These diseases can appear at any
age and, generally speaking, they have a greater reper-
cussions on the quality of life of women. Dermatological
conditions often alter the patient’s own body image,
which can cause psychological problems such as depres-
sion, anxiety and even suicide. OBJECTIVE: To evaluate
the depressive symptomatology (DS) of patients with 
psoriasis. The CES-D (Center for Epidemiologic Studies—
Depression scale), a short self-report scale composed of
20 items, is a questionnaire designed to measure DS in
the general population. The CES-D is widely used in epi-
demiological surveys on large populations. METHOD:
One thousand ﬁve hundred CES-D questionnaires were
sent via a psoriasis patients support group: the APLCP.
The questionnaires once completed were sent back trough
a prepaid envelope. RESULTS: Six hundred thirty-seven
questionnaires were returned: response rate: 42.5%. The
sex ratio Men/Women was 46/54. Mean age: 48.9 years.
Mean age of diagnosis: 25.7 years. The average to the
total score was 20.9 (sd:12.5). The preliminary results
showed DS in 48% of patients with psoriasis (versus 19%
in the general population). There is DS in 47.1% of men
and 49.0% of women. Two groups were identiﬁed: 
ﬂare-up of psoriasis (46.7%), psoriasis not in ﬂare-up
(51.8%)—no answers (1.5%). Current episode of 
psoriasis are linked with higher frequency of DS (54.3%
versus 42.4%). Psoriasis had a greater impact on patients
with episode: CES-D score: 22.8 (sd:12.74) than patients
without present episode CES-D score : 19.22 (s.d :11.96).
This difference was signiﬁcant (p < 0.0003). CONCLU-
SION: Psoriasis patients have an increased risk of DS
compared to the general population (48% versus 19%).
A recent episode of psoriasis results in a more important
frequency of DS in patients (54.3% versus 42.4%).
Appropriate disease management and any treatment that
could reduce ﬂare-up frequency would improve patients’
quality of life and help them face their psoriasis.
EAR, EYE & SKIN DISEASES/DISORDERS—Quality
of Life/Utility
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OBJECTIVES: To evaluate the consequences of local
anti-glaucoma drug side effects on the vision-related
quality of life of French patients. METHODS: A mail
survey was sent to 20,000 homes belonging to the Sofres
panel (representative of the French population according
to the quota method) asking whether one member of 
the family was treated with one of the available topical
anti-glaucoma drugs. A computer-assisted telephone
interviewing system was used to conﬁrm self-reported
glaucoma treatment, to describe the disease and its treat-
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ment, as well as medical item consumption. Vision-
related QoL was assessed with the NEI-VFQ-25 and local
tolerance with the COMTOL. RESULTS: Thirteen 
thousand three hundred and ﬁfty-two homes (66.7%)
answered the mail. Five hundred eighty-one people
declared they were treated for glaucoma, leading to glau-
coma and ocular hypertension treatment prevalence of
1.8%, increasing with age. Of those with glaucoma, 173
patients under treatment at the time of the interview were
selected at random. Their NEI-VFQ-25 global score was
high showing an overall good QoL. Two domain scores
showed some deterioration: general health and driving.
COMTOL results identiﬁed 62.4% of the patients cited
at least one local side effect: 25.4% had burning, 20.8%
blurred vision and 20.2% tearing amongst others. Vision
related QoL was affected by local side effects (up to
34.4%) leading to poor perceived treatment satisfac-
tion that impacted compliance. Burning and stinging,
dimming of vision, focusing from near to far and trouble
seeing at night intensively affected QoL (P < 0.001) while
redness, unusual taste and discharge from the eye did 
not reach the 0.10 P-Value. Dissatisﬁed patients visited
their ophthalmologist more frequently leading to extra
expenses. CONCLUSION: Based on a representative
French sample, vision related QoL is affected by topical
drug side effects that also impact patient satisfaction,
compliance and cost.
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OBJECTIVE: To develop an instrument to assess the
impact of ocular allergy symptoms. General health and
allergy questionnaires do not adequately address the spe-
ciﬁc concerns of patients who suffer from chronic and/
or seasonal ocular allergies and see ophthalmologists.
METHODS: We modiﬁed an instrument, the Dry Eye
Disease Impact Questionnaire (DEDIQ), to create the
pretest version of the EAPIQ. Following pretesting with
a small group of patients the EAPIQ was administered
along with the MiniRQLQ, a rhinoconjunctivitis instru-
ment developed by Juniper et al., in a randomized clini-
cal trial studying a new ocular allergy treatment (300 US
patients). To facilitate global use, we tested the EAPIQ
with 48 allergy patients in 4 European countries, fol-
lowed by focus groups to gain input on relevance of items
and satisfaction with EAPIQ administration. RESULTS:
Face validity was demonstrated in the initial pretest of the
questionnaire. Modiﬁcations were made for use in the
clinical trial. Many items (e.g. limitation reading and
driving, days symptoms interfered with leisure activities)
on the EAPIQ were found to correlate with patient
reports of symptoms (itching) and the mRQLQ. 
European patients generally felt the EAPIQ addressed
their concerns and suggested few changes to the ques-
tionnaire, including reducing the number of redundant
items and standardizing the scaling options. The 48 
participants had a mean age of 37 years and 52% were
female. 78% reported use of allergy treatments 2–3 
times daily. The most bothersome symptoms were itchy 
eyes (52%) and watery eyes (23%). Most patients felt 
irritable, embarrassed or self-conscious a “good-bit-of
time” due to their eye allergy symptoms. CONCLUSION:
The EAPIQ is a disease speciﬁc instrument that captures
and addresses the symptomatic, outcomes, and QOL con-
cerns of patients suffering from seasonal and chronic
ocular allergy symptoms. A revised-ﬁnal version of the
EAPIQ is currently undergoing testing in a multinational
validation study.
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OBJECTIVES: Using data from a prospective, random-
ized, double blind clinical trial comparing olopatadine to
levocabastine in patients with Seasonal Allergic Conjunc-
tivitis (SAC), two synthetic scores, summarizing recorded
effectiveness information one being a single-dimensional
symptoms score and the other a quality-of-life (QOL)
measure were derived. We then compared the two mea-
sures in various national contexts. METHODS: Corre-
spondence analysis was used to analyze the study results.
Coordinates on the ﬁrst factorial axis were transformed
into an aggregate symptom score and averaged across
patients at each visit. At the same time, 32 experts from
6 European countries were asked to quantify the impact
of each level of each symptom on QOL from a patient’s
perspective. They were also asked to weigh on each
symptom. An aggregated QOL score was thus derived
and averaged across patients in both arms. RESULTS: At
baseline, aggregated symptoms scores were identical
across both groups of patients (p = 0.798). At day 42, the
score in the olopatadine branch was signiﬁcantly better
than that in the levocabastine arm (p = 0.032). QOL life
scores exhibited the same pattern of improvement. Com-
parisons between scores show that QOL score is posi-
tively, but not linearly, correlated to the symptom score.
For high levels of symptom severity, a clinical improve-
ment, measured in terms of a reduction of symptoms
intensity, offers little QOL improvement, while the same
improvement, starting from a lower level of symptom
score, offers an important QOL improvement. CON-
CLUSION: The indicators constructed from the study
data exhibit several interesting properties. Although they
have strong clinical signiﬁcance, they do not describe the
